Tazverik (Tazemetostat Hydrobromide) Patent Expiration, LOE Window & CMS Spending
Tazverik (Tazemetostat Hydrobromide) by Epizyme: FDA Orange Book core substance LOE 2034-01-23 (last listed 2038-05-03), 0 AB generics, $28.8M 2024 CMS Part D & Medicaid spend.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Epizyme |
| FDA Application & Pathway | N213400 (NDA) |
| Exclusivity / Cliff Horizon | Long-Dated Protection (2036+) |
| Core Active-Ingredient LOE Date | 2034-01-23 |
| Last Listed Patent or Exclusivity Date | 2038-05-03 |
| Orange Book Patents (*PED Extensions) | 27 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 0 |
| 2024 CMS Total Public Spend | $28.8M |
| 2024 Medicare Part D Spend | $25.1M |
| 2024 Medicaid Spend | $3.7M |
| Reported Wholesale Price Change (CA SB 17) | 0 statutory filings in 2023 to 2026 panel |